[ XXXX in spontaneous @entity951 : double-blind cross-over study with Holter monitoring].

@entity1 @entity308 @entity63 @entity3988 @entity10260 @entity951
Using Holter monitoring the Authors compared the effectiveness of @entity3988 120 mg every 8 hours for three consecutive days with the results of a placebo administered with the same regimen, following a double-blind completely balanced cross-over trial in 20 @entity1 with @entity951 at rest. During treatment with @entity3988 the total number of recorded @entity63 episodes was 100, during treatment with placebo the total number was 357 (Tab. I); P less than 0.01 at analysis of variance (Tab. II). @entity63 episodes during treatment with @entity3988 had a shorter duration (3.9 versus 5.1 min.), less marked @entity10260 segment shifts (1.3 versus 2 mm), and were less symptomatic (20% versus 29%) than @entity63 episodes during placebo (Tab. III). No significant differences at a paired t test were noted. @entity3988 was more effective in the morning (12 p.m. - 12 a.m.: from 187 to 34 @entity63 episodes) than in the evening (12 a.m. - 12 p.m.: from 170 to 66 @entity63 episodes) (Fig. 1); P less than 0.01 at the chi-square test (Tab. IV). @entity3988 reduced the number of @entity63 episodes with @entity10260 segment elevation, peaking of T waves and negative T wave inversion (from 188 to 39) more than the number of episodes with @entity308 (from 169 to 61) (Tab. V); P less than 0.05 at the chi-square test. In conclusion, in @entity1 with @entity951 at rest, @entity3988 reduces the incidence and seems to reduce the severity of @entity63 episodes, too.(ABSTRACT TRUNCATED AT 250 WORDS)
